Pharmacologic and Clinical Profile of Tramadol

Mechanism of Action

Tramadol acts as a weak mu‑opioid receptor agonist and simultaneously inhibits reuptake of serotonin and norepinephrine, providing analgesia through dual pathways. (Mayo Clinic/NeuPSIG; NCCN) 1

Compared with morphine, tramadol’s analgesic potency is roughly one‑tenth, reflecting its substantially lower mu‑opioid receptor affinity. (NCCN) 2
In the United States, tramadol was originally not scheduled as a controlled substance, although scheduling may differ by jurisdiction. (Mayo Clinic/NeuPSIG) 1
Because of its combined opioid and monoamine‑reuptake actions, tramadol is classified as an “atypical opioid” rather than a traditional pure opioid agonist. (NCCN) 2

The Mayo Clinic/NeuPSIG guidelines list tramadol as a second‑line option for neuropathic pain; it may be considered first‑line only in selected situations such as acute neuropathic pain, cancer‑related neuropathic pain, or episodic severe pain flares. (Mayo Clinic/NeuPSIG) 1

NCCN guidelines place tramadol in a separate “miscellaneous analgesics” category for cancer pain, distinguishing it from conventional opioids because of its dual mechanism. (NCCN) 2

Tramadol’s serotonergic activity can precipitate serotonin syndrome when co‑administered with serotonergic agents (e.g., SSRIs, SNRIs, MAOIs, tricyclic antidepressants), a reaction not typical of pure opioid agonists. (Mayo Clinic/NeuPSIG; NCCN) 1

Tramadol lowers the seizure threshold, with heightened risk in patients who have hepatic or renal impairment or in older adults (approximately ≥ 75 years). (Mayo Clinic/NeuPSIG; NCCN) 1

The 2022 CDC Opioid Prescribing Guideline advises that tramadol therapy for chronic pain should be limited to the shortest effective duration, with frequent reassessment of benefits versus harms. 3

When a tramadol prescription exceeds 7–14 days, clinicians should document a clear pain diagnosis, set functional goals, and arrange follow‑up within 1–4 weeks to evaluate efficacy, adverse effects, and ongoing need. 3

An early reassessment is recommended at 7–14 days after initiating tramadol to review pain relief, functional improvement, side‑effects, and the necessity of continuation. 3

If tramadol is continued beyond 2 weeks, the prescriber must document specific functional objectives, create a treatment plan with defined endpoints, and schedule regular follow‑up visits every 1–4 weeks. 3

Tramadol should not be continued beyond 2 weeks without documented reassessment of pain intensity, functional status, and adverse events, in accordance with CDC recommendations. 3